Stoke Therapeutics, Inc. (STOK) Stock Analysis and Metrics

Stoke Therapeutics

NASDAQ: STOK

$29.32 ▼ -0.33 (-1.11%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.86 Bn

P/E-10.65

P/S57.83

Div. Yield0.00

Revenue Growth (1y) (Qtr)-96.07

Add ratio to table…

About

Stoke Therapeutics, Inc. is a late-stage clinical company dedicated to addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach to develop antisense oligonucleotides (ASOs) that selectively restore protein levels. Its primary focus is on genetic diseases of the central nervous system and the eye, with lead programs targeting haploinsufficiency disorders.

Stoke Therapeutics generates revenue through upfront payments, milestone payments, and royalties from collaboration agreements with biopharmaceutical partners. The company does not currently have any commercialized products or direct product sales revenue. Revenue is derived from licensing and development partnerships, including agreements with Acadia Pharmaceuticals and Biogen, which provide upfront payments, potential milestone payments, and tiered royalties on future net sales of licensed products.

The company operates through the following segments: TANGO platform development and clinical programs.

• TANGO platform development: This segment encompasses the company's proprietary RNA therapeutics platform designed to increase protein expression from healthy genes to compensate for mutated, non-functioning copies. The TANGO approach uses antisense oligonucleotides to modulate pre-mRNA splicing and prevent non-productive alternative splicing, thereby increasing productive mRNA and protein levels. The platform is applied across multiple disease areas, including central nervous system and eye disorders, and is supported by proprietary bioinformatics algorithms and in-house expertise in whole-transcriptome RNA sequencing.

• Clinical programs: This segment includes the advancement of product candidates through preclinical and clinical development. The lead candidate, zorevunersen (STK-001), is in global Phase 3 development for Dravet syndrome under the EMPEROR study. The second candidate, STK-002, is in Phase 1 development for autosomal dominant optic atrophy (ADOA) via the OSPREY study. Additional preclinical programs target haploinsufficiency diseases of the central nervous system, eye, and heart, leveraging the TANGO mechanism to upregulate protein expression from wild-type alleles.

Stoke Therapeutics occupies a pioneering position in the field of genetic medicines for autosomal dominant haploinsufficiencies, a space with limited competition due to the unique mechanism of its TANGO platform. While other companies develop antisense oligonucleotides or gene therapies, few focus on upregulating protein expression via non-productive splicing correction in haploinsufficiency diseases. The company's competitive advantages include its mutation-independent approach, tissue-specific activity, and ability to address multiple mutations in a single gene with a single drug, supported by strong intellectual property and clinical data from its lead programs.

Stoke Therapeutics serves patients with severe genetic diseases, particularly those with Dravet syndrome and autosomal dominant optic atrophy, as well as their families and caregivers. The company collaborates with healthcare providers, treatment centers, and clinical sites to identify and access eligible patients through genetic testing. Its customer base includes pediatric and adult patients diagnosed with specific genetic mutations in the SCN1A and OPA1 genes, who are enrolled in clinical studies or potential future recipients of approved therapies.

Investment Thesis

▲ Bull case

Stoke Therapeutics (Nasdaq: STOK) possesses a robust financial runway supported by $391.7 million in cash, cash equivalents, and marketable securities as of December 31, 2025, which is projected to fund operations through 2028 when combined with eligible proceeds from the Biogen collaboration, providing ample resources to advance zorevunersen through pivotal Phase 3 development and commercialization without near-term financing pressure. This strong liquidity position reduces execution risk and allows the company to maintain focus on clinical milestones rather than dilutive fundraising, particularly important given the extended timelines typical in CNS drug development and the company’s strategic shift toward commercial preparedness as highlighted by management. The financial stability enables investment in manufacturing scale-up, commercial infrastructure, and pipeline expansion—including STK-002 for ADOA—without compromising the core Dravet syndrome program, positioning Stoke to capitalize on zorevunersen’s potential U.S. launch in early 2028 if Phase 3 results are favorable. Furthermore, the company’s ability to sustain operations through multiple value inflection points, such as the mid-2027 EMPEROR study readout and potential NDA submission, creates optionality that the market may be underestimating in its current valuation.
The accumulating long-term clinical evidence from zorevunersen’s Phase 1/2a and open-label extension (OLE) studies reveals a compelling disease-modifying signal that extends beyond seizure reduction to meaningful improvements in neurodevelopment, cognition, and behavior, with statistically significant benefits demonstrated at 1, 2, 3, and 4 years of treatment compared to OLE baseline—data that are rare in epilepsy therapeutics and suggest a potential to alter the developmental trajectory of Dravet syndrome. These multi-year outcomes, combined with the drug’s favorable tolerability profile (including patients treated for over five years), address critical unmet needs in a population where up to 57% fail to achieve ≥50% seizure reduction with current anti-seizure medicines and up to 20% face mortality risk before adulthood, underscoring the therapeutic opportunity. The durability of effect observed in the OLE studies supports the likelihood of a positive Phase 3 EMPEROR study outcome, particularly given the mechanistic rationale of increasing functional NaV1.1 protein from the wild-type SCN1A allele, and could enable label expansion beyond seizure frequency to include cognitive and behavioral endpoints—potentially differentiating zorevunersen from symptomatic therapies and strengthening its commercial value proposition.
Stoke’s strategic collaboration with Biogen provides a significant de-risking factor and commercial catalyst that the market may not be fully pricing in, as it grants Stoke exclusive rights to zorevunersen in the United States, Canada, and Mexico while Biogen handles rest-of-world commercialization, allowing Stoke to retain full profit potential in its core geographic markets while leveraging Biogen’s global scale and rare disease expertise outside North America. This structure mitigates the burden of building a worldwide commercial organization—a major challenge for small biotechs—while ensuring Stoke captures the majority of economic value given the U.S. represents the largest market for Dravet syndrome therapies. Additionally, Biogen’s involvement validates the science and increases the likelihood of successful commercial execution, particularly as the company prepares for a potential U.S. launch in early 2028 following anticipated mid-2027 Phase 3 data and a rolling NDA submission in Q1 FY27. The partnership also provides non-dilutive funding through milestones and royalties, further extending Stoke’s cash runway and reducing reliance on equity markets, which is especially valuable in volatile biotech financing environments.
The accelerated enrollment timeline for the Phase 3 EMPEROR study—now targeting completion in Q2 FY26 (June 2026) with data readout on track for mid-2027—demonstrates strong clinical site engagement and patient demand, reflecting both the high unmet need in Dravet syndrome and growing investigator confidence in zorevunersen’s potential, which reduces a key execution risk that often delays pivotal trials in rare neurodegenerative diseases. This progress, combined with the ongoing FDA dialogue under Breakthrough Therapy Designation, positions Stoke to potentially initiate a rolling NDA submission in the first half of 2027 (H1 FY27), earlier than many analysts may expect, thereby compressing the timeline to potential approval and U.S. launch in early 2028. The FDA’s request for additional information and continued discussions signal active engagement rather than skepticism, increasing the probability of favorable regulatory feedback and possible expedited pathways, which could further accelerate timelines beyond current guidance. Such regulatory momentum, coupled with the drug’s orphan, rare pediatric, and Breakthrough Therapy designations, creates a supportive environment for approval that the market may be underappreciating in light of the historical challenges in CNS drug development.

Stoke Therapeutics (Nasdaq: STOK) possesses a robust financial runway supported by $391.7 million in cash, cash equivalents, and marketable securities as of December 31, 2025, which is projected to fund operations through 2028 when combined with eligible proceeds from the Biogen collaboration, providing ample resources to advance zorevunersen through pivotal Phase 3 development and commercialization without near-term financing pressure. This strong liquidity position reduces execution risk and allows the company to maintain focus on clinical milestones rather than dilutive fundraising, particularly important given the extended timelines typical in CNS drug development and the company’s strategic shift toward commercial preparedness as highlighted by management. The financial stability enables investment in manufacturing scale-up, commercial infrastructure, and pipeline expansion—including STK-002 for ADOA—without compromising the core Dravet syndrome program, positioning Stoke to capitalize on zorevunersen’s potential U.S. launch in early 2028 if Phase 3 results are favorable. Furthermore, the company’s ability to sustain operations through multiple value inflection points, such as the mid-2027 EMPEROR study readout and potential NDA submission, creates optionality that the market may be underestimating in its current valuation.
The accumulating long-term clinical evidence from zorevunersen’s Phase 1/2a and open-label extension (OLE) studies reveals a compelling disease-modifying signal that extends beyond seizure reduction to meaningful improvements in neurodevelopment, cognition, and behavior, with statistically significant benefits demonstrated at 1, 2, 3, and 4 years of treatment compared to OLE baseline—data that are rare in epilepsy therapeutics and suggest a potential to alter the developmental trajectory of Dravet syndrome. These multi-year outcomes, combined with the drug’s favorable tolerability profile (including patients treated for over five years), address critical unmet needs in a population where up to 57% fail to achieve ≥50% seizure reduction with current anti-seizure medicines and up to 20% face mortality risk before adulthood, underscoring the therapeutic opportunity. The durability of effect observed in the OLE studies supports the likelihood of a positive Phase 3 EMPEROR study outcome, particularly given the mechanistic rationale of increasing functional NaV1.1 protein from the wild-type SCN1A allele, and could enable label expansion beyond seizure frequency to include cognitive and behavioral endpoints—potentially differentiating zorevunersen from symptomatic therapies and strengthening its commercial value proposition.
Stoke’s strategic collaboration with Biogen provides a significant de-risking factor and commercial catalyst that the market may not be fully pricing in, as it grants Stoke exclusive rights to zorevunersen in the United States, Canada, and Mexico while Biogen handles rest-of-world commercialization, allowing Stoke to retain full profit potential in its core geographic markets while leveraging Biogen’s global scale and rare disease expertise outside North America. This structure mitigates the burden of building a worldwide commercial organization—a major challenge for small biotechs—while ensuring Stoke captures the majority of economic value given the U.S. represents the largest market for Dravet syndrome therapies. Additionally, Biogen’s involvement validates the science and increases the likelihood of successful commercial execution, particularly as the company prepares for a potential U.S. launch in early 2028 following anticipated mid-2027 Phase 3 data and a rolling NDA submission in Q1 FY27. The partnership also provides non-dilutive funding through milestones and royalties, further extending Stoke’s cash runway and reducing reliance on equity markets, which is especially valuable in volatile biotech financing environments.
The accelerated enrollment timeline for the Phase 3 EMPEROR study—now targeting completion in Q2 FY26 (June 2026) with data readout on track for mid-2027—demonstrates strong clinical site engagement and patient demand, reflecting both the high unmet need in Dravet syndrome and growing investigator confidence in zorevunersen’s potential, which reduces a key execution risk that often delays pivotal trials in rare neurodegenerative diseases. This progress, combined with the ongoing FDA dialogue under Breakthrough Therapy Designation, positions Stoke to potentially initiate a rolling NDA submission in the first half of 2027 (H1 FY27), earlier than many analysts may expect, thereby compressing the timeline to potential approval and U.S. launch in early 2028. The FDA’s request for additional information and continued discussions signal active engagement rather than skepticism, increasing the probability of favorable regulatory feedback and possible expedited pathways, which could further accelerate timelines beyond current guidance. Such regulatory momentum, coupled with the drug’s orphan, rare pediatric, and Breakthrough Therapy designations, creates a supportive environment for approval that the market may be underappreciating in light of the historical challenges in CNS drug development.

▼ Bear case

Stoke Therapeutics (Nasdaq: STOK) faces significant execution risk in advancing zorevunersen to market despite positive early data, as the Phase 3 EMPEROR study’s success is not guaranteed and historical precedent shows that promising Phase 1/2a results in CNS disorders frequently fail to replicate in larger, controlled pivotal trials due to placebo effects, heterogeneity in patient populations, or inadequate dosing—risks underscored by the company’s own cautionary language about the inability to replicate early-stage successes in later trials and the absence of any regulatory evaluation of safety or efficacy to date. The reliance on a single primary endpoint (percent change in major motor seizure frequency at week 28) increases vulnerability to statistical noise or unforeseen safety signals, particularly given the invasive intrathecal delivery method and chronic dosing regimen, which could impact patient retention and long-term adherence—factors not fully captured in the open-label extension studies that lack a control group. Without corroborating evidence from a well-controlled, adequately powered Phase 3 trial, the market may be overestimating the probability of approval based on exploratory OLE data that, while encouraging, are susceptible to bias and cannot establish causality.
The commercial opportunity for zorevunersen may be substantially constrained by the ultra-rare nature of Dravet syndrome, with an estimated U.S. prevalence of only ~16,000 patients, which limits peak sales potential even assuming high penetration and premium pricing, especially when weighed against the substantial costs of manufacturing, distributing, and administering an intrathecal antisense oligonucleotide requiring specialized clinical infrastructure and repeated lumbar punctures every four months—a burden that may deter adoption among neurologists and caregivers accustomed to oral or topical anti-seizure regimens. Furthermore, the presence of established (though symptomatic) therapies and the lack of proven disease-modifying alternatives create uncertainty about reimbursement willingness, as payers may demand robust evidence of long-term cost savings or hospitalization reduction before granting broad formulary access, a bar that has not yet been met by any Dravet syndrome therapy. The company’s focus on neurodevelopmental and behavioral endpoints, while scientifically compelling, may not translate into reimbursement advantages if payers prioritize seizure reduction as the primary value driver, potentially limiting pricing power and market uptake despite any cognitive benefits observed in early studies.
Stoke’s dependence on its collaboration with Biogen introduces material counterparty risk, as the success of zorevunersen’s global commercialization hinges on Biogen’s ability and willingness to invest in and execute outside the U.S., Canada, and Mexico—a risk amplified by Biogen’s recent strategic shifts, including portfolio prioritization and cost-cutting measures in its neuroscience franchise, which could delay or diminish rest-of-world commercialization efforts despite the contractual agreement. While Stoke retains North American rights, the loss of Biogen’s partnership would eliminate a key source of non-dilutive funding, validation, and operational support, potentially forcing the company to seek alternative partners on less favorable terms or delay international expansion altogether. Moreover, any disagreement over pricing, market access strategy, or trial conduct could strain the relationship, and the company’s cautious disclosure that no immediate changes were agreed upon in the recent FDA meeting—coupled with ongoing discussions—suggests unresolved alignment on regulatory strategy that could complicate development if priorities diverge. This reliance on a single large partner for critical aspects of the program creates vulnerability that may not be fully reflected in the current valuation.
The expansion beyond zorevunersen into earlier-stage programs like STK-002 for ADOA, while scientifically plausible, risks diverting managerial focus, financial resources, and organizational bandwidth from the critical path of delivering zorevunersen to market, particularly as the company prepares for Phase 3 readout, NDA submission, and commercial launch—activities that demand intense cross-functional coordination. The initiation of the OSPREY study and ongoing dose escalation through 2027 requires investment in clinical sites, manufacturing, and regulatory planning, all of which draw from the same finite cash pool and leadership attention, even if funded separately. Management’s repeated emphasis on “building our pipeline for the future” alongside commercial preparedness signals a potential dual-focus strategy that could dilute execution excellence on the near-term catalyst, especially given the historical difficulty biotechs face in advancing multiple programs in parallel without compromising core objectives. Unless STK-002 demonstrates clear and rapid proof of concept, its continued development may represent an opportunity cost that delays or undermines the zorevunersen timeline, a trade-off the market may not be adequately weighing against the binary nature of the Phase 3 outcome.

Stoke Therapeutics (Nasdaq: STOK) faces significant execution risk in advancing zorevunersen to market despite positive early data, as the Phase 3 EMPEROR study’s success is not guaranteed and historical precedent shows that promising Phase 1/2a results in CNS disorders frequently fail to replicate in larger, controlled pivotal trials due to placebo effects, heterogeneity in patient populations, or inadequate dosing—risks underscored by the company’s own cautionary language about the inability to replicate early-stage successes in later trials and the absence of any regulatory evaluation of safety or efficacy to date. The reliance on a single primary endpoint (percent change in major motor seizure frequency at week 28) increases vulnerability to statistical noise or unforeseen safety signals, particularly given the invasive intrathecal delivery method and chronic dosing regimen, which could impact patient retention and long-term adherence—factors not fully captured in the open-label extension studies that lack a control group. Without corroborating evidence from a well-controlled, adequately powered Phase 3 trial, the market may be overestimating the probability of approval based on exploratory OLE data that, while encouraging, are susceptible to bias and cannot establish causality.
The commercial opportunity for zorevunersen may be substantially constrained by the ultra-rare nature of Dravet syndrome, with an estimated U.S. prevalence of only ~16,000 patients, which limits peak sales potential even assuming high penetration and premium pricing, especially when weighed against the substantial costs of manufacturing, distributing, and administering an intrathecal antisense oligonucleotide requiring specialized clinical infrastructure and repeated lumbar punctures every four months—a burden that may deter adoption among neurologists and caregivers accustomed to oral or topical anti-seizure regimens. Furthermore, the presence of established (though symptomatic) therapies and the lack of proven disease-modifying alternatives create uncertainty about reimbursement willingness, as payers may demand robust evidence of long-term cost savings or hospitalization reduction before granting broad formulary access, a bar that has not yet been met by any Dravet syndrome therapy. The company’s focus on neurodevelopmental and behavioral endpoints, while scientifically compelling, may not translate into reimbursement advantages if payers prioritize seizure reduction as the primary value driver, potentially limiting pricing power and market uptake despite any cognitive benefits observed in early studies.
Stoke’s dependence on its collaboration with Biogen introduces material counterparty risk, as the success of zorevunersen’s global commercialization hinges on Biogen’s ability and willingness to invest in and execute outside the U.S., Canada, and Mexico—a risk amplified by Biogen’s recent strategic shifts, including portfolio prioritization and cost-cutting measures in its neuroscience franchise, which could delay or diminish rest-of-world commercialization efforts despite the contractual agreement. While Stoke retains North American rights, the loss of Biogen’s partnership would eliminate a key source of non-dilutive funding, validation, and operational support, potentially forcing the company to seek alternative partners on less favorable terms or delay international expansion altogether. Moreover, any disagreement over pricing, market access strategy, or trial conduct could strain the relationship, and the company’s cautious disclosure that no immediate changes were agreed upon in the recent FDA meeting—coupled with ongoing discussions—suggests unresolved alignment on regulatory strategy that could complicate development if priorities diverge. This reliance on a single large partner for critical aspects of the program creates vulnerability that may not be fully reflected in the current valuation.
The expansion beyond zorevunersen into earlier-stage programs like STK-002 for ADOA, while scientifically plausible, risks diverting managerial focus, financial resources, and organizational bandwidth from the critical path of delivering zorevunersen to market, particularly as the company prepares for Phase 3 readout, NDA submission, and commercial launch—activities that demand intense cross-functional coordination. The initiation of the OSPREY study and ongoing dose escalation through 2027 requires investment in clinical sites, manufacturing, and regulatory planning, all of which draw from the same finite cash pool and leadership attention, even if funded separately. Management’s repeated emphasis on “building our pipeline for the future” alongside commercial preparedness signals a potential dual-focus strategy that could dilute execution excellence on the near-term catalyst, especially given the historical difficulty biotechs face in advancing multiple programs in parallel without compromising core objectives. Unless STK-002 demonstrates clear and rapid proof of concept, its continued development may represent an opportunity cost that delays or undermines the zorevunersen timeline, a trade-off the market may not be adequately weighing against the binary nature of the Phase 3 outcome.

Product and Service Breakdown of Revenue (2024)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2024)

Product and Service Breakdown of Revenue (2024)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2024)

Product and Service Breakdown of Revenue (2024)

Peer Comparison

Create an account

Sign In

Reset Password